Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Meet our Council Members: Derek Foster, ethical and responsible leadership role model
2016-05-18

Description: 2016 05 18 Derek Foster Tags: 2016 05 18 Derek FosterMr Derek Foster
Photo: Stephen Collett

Derek Foster was elected to the Council of the University of the Free State (UFS) in October 2012. He was the first Chartered Accountant (South Africa) to be appointed to Council because of the role he could play through his training, background, and experience. In particular, it was his knowledge of corporate governance, ethics, and reporting that led to his serving currently on the Audit and Risk Committee, the Finance Committee, and the Investment Committee of Council.

This Kovsie alumnus qualified as chartered accountant at the UFS in 1978. During his student years, he played rugby for Oud-Studente, and served in the Evening Student Representative Council.

Until December 2010, Derek was a partner in PricewaterhouseCoopers, which he joined in 1972 as a rookie when the company was still known as Meyer, Nel and Co. Nowadays, he is a business consultant and company director, serving on the boards of NWK Limited, Cancer Association of South Africa (national), and Samba Cooperative Limited.

His background and knowledge of auditing shine through strongly when it comes to the manner in which he sees his role as Council member. “The contribution which I can make to the Council of the university is to ensure that management executes strategy and policy appropriately, as formulated and approved by Council, in the best interest of the university community. Of course, this should be done in an ethical, sustainable manner, taking into account the risk environment we find ourselves in. We need to provide ethical leadership, and ensure that the UFS is a responsible corporate institution,” he says.

Work obligations are keeping him very busy, but his four grandsons are equally high on his priority list. He met his wife, Sally, at Kovsies, another reason why the university is close to his heart. “Everything I do, I want to do with enthusiasm and passion, and I want to make a difference wherever I go. I would also like to be a good grandfather, and set a memorable example to my grandchildren,” he says.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept